A detailed history of Oppenheimer & CO Inc transactions in Protara Therapeutics, Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 206,973 shares of TARA stock, worth $1.14 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
206,973
Previous 246,064 15.89%
Holding current value
$1.14 Million
Previous $745,000 20.81%
% of portfolio
0.01%
Previous 0.01%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 05, 2025

SELL
$2.78 - $4.41 $108,672 - $172,391
-39,091 Reduced 15.89%
206,973 $900,000
Q2 2025

Jul 31, 2025

BUY
$2.88 - $4.42 $171,360 - $262,990
59,500 Added 31.89%
246,064 $745,000
Q1 2025

Apr 22, 2025

SELL
$3.37 - $6.14 $50,084 - $91,252
-14,862 Reduced 7.38%
186,564 $794,000
Q4 2024

Feb 04, 2025

BUY
$1.68 - $7.53 $37,465 - $167,926
22,301 Added 12.45%
201,426 $1.06 Million
Q3 2024

Nov 05, 2024

BUY
$1.7 - $2.4 $88,304 - $124,665
51,944 Added 40.84%
179,125 $327,000
Q2 2024

Aug 07, 2024

BUY
$1.96 - $4.14 $229,674 - $485,129
117,181 Added 1171.81%
127,181 $264,000
Q1 2024

May 06, 2024

BUY
$1.86 - $4.83 $18,600 - $48,300
10,000 New
10,000 $40,000

Others Institutions Holding TARA

About Protara Therapeutics, Inc.


  • Ticker TARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,267,400
  • Market Cap $62.1M
  • Description
  • Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...
More about TARA
Track This Portfolio

Track Oppenheimer & CO Inc Portfolio

Follow Oppenheimer & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer & CO Inc with notifications on news.